Vaccine safety in children with genetically confirmed mitochondrial disease

IF 3.3 4区医学 Q3 IMMUNOLOGY

Immunology letters Pub Date : 2024-11-17 DOI:10.1016/j.imlet.2024.106946

Annemarie de Vreugd , Franz A. Zimmermann , Katja Steinbrücker , Maaike C. de Vries , Lonneke de Boer , Mirian CH Janssen , Martina Huemer , Saskia B. Wortmann

{"title":"Vaccine safety in children with genetically confirmed mitochondrial disease","authors":"Annemarie de Vreugd , Franz A. Zimmermann , Katja Steinbrücker , Maaike C. de Vries , Lonneke de Boer , Mirian CH Janssen , Martina Huemer , Saskia B. Wortmann","doi":"10.1016/j.imlet.2024.106946","DOIUrl":null,"url":null,"abstract":"<div><div>We here explore adverse events following immunization (AEFI) in children with mitochondrial disease (MD) recruited from two expertise centers in Austria (SALK) and The Netherlands (RUMC). Parents completed a questionnaire on the type of immunizations received and AEFI in a post-vaccination exposure period of seven days.</div><div>95 individuals were invited to this study, of whom 30 (median age 13.4 years) participated. Together these individuals had received 376 immunizations with a median of 12 vaccinations each. In 316 of 376 (84 %) vaccinations no AEFI occurred, 22 patients (73 %) never experienced any AEFI. Eight patients experienced 76 AEFI after 60 vaccinations, these were mild (redness (<em>n</em> = 9) /pain at injection site (<em>n</em> = 21), fever (<em>n</em> = 44), gastrointestinal complaints (<em>n</em> = 2)). None had a metabolic deterioration or seizures, no patient was admitted to the hospital.</div><div>Although our data is limited by the small sample size, this may aid in discussing responsible immunization decisions with parents.</div></div>","PeriodicalId":13413,"journal":{"name":"Immunology letters","volume":"271 ","pages":"Article 106946"},"PeriodicalIF":3.3000,"publicationDate":"2024-11-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Immunology letters","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0165247824001202","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"IMMUNOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

We here explore adverse events following immunization (AEFI) in children with mitochondrial disease (MD) recruited from two expertise centers in Austria (SALK) and The Netherlands (RUMC). Parents completed a questionnaire on the type of immunizations received and AEFI in a post-vaccination exposure period of seven days.

95 individuals were invited to this study, of whom 30 (median age 13.4 years) participated. Together these individuals had received 376 immunizations with a median of 12 vaccinations each. In 316 of 376 (84 %) vaccinations no AEFI occurred, 22 patients (73 %) never experienced any AEFI. Eight patients experienced 76 AEFI after 60 vaccinations, these were mild (redness (n = 9) /pain at injection site (n = 21), fever (n = 44), gastrointestinal complaints (n = 2)). None had a metabolic deterioration or seizures, no patient was admitted to the hospital.

Although our data is limited by the small sample size, this may aid in discussing responsible immunization decisions with parents.

查看原文本刊更多论文

经基因证实患有线粒体疾病的儿童接种疫苗的安全性。

我们在此探讨从奥地利（SALK）和荷兰（RUMC）两家专业中心招募的线粒体疾病（MD）患儿的免疫接种后不良事件（AEFI）。家长们填写了一份调查问卷，内容涉及所接受的免疫接种类型以及接种后七天内的AEFI情况。这项研究邀请了 95 人参加，其中 30 人（中位数年龄为 13.4 岁）参加了研究。这些人共接受了 376 次免疫接种，每次接种的中位数为 12 次。在 376 次接种中，有 316 次（84%）没有发生 AEFI，有 22 名患者（73%）从未发生过 AEFI。8 名患者在接种 60 次疫苗后出现了 76 例 AEFI，症状轻微（注射部位发红（9 例）/疼痛（21 例）、发烧（44 例）、胃肠不适（2 例））。没有人出现新陈代谢恶化或癫痫发作，也没有人入院治疗。虽然我们的数据因样本量较小而受到限制，但这可能有助于与家长讨论负责任的免疫接种决定。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Immunology letters 医学-免疫学

CiteScore

7.60

自引率

0.00%

发文量

审稿时长

44 days

期刊介绍： Immunology Letters provides a vehicle for the speedy publication of experimental papers, (mini)Reviews and Letters to the Editor addressing all aspects of molecular and cellular immunology. The essential criteria for publication will be clarity, experimental soundness and novelty. Results contradictory to current accepted thinking or ideas divergent from actual dogmas will be considered for publication provided that they are based on solid experimental findings. Preference will be given to papers of immediate importance to other investigators, either by their experimental data, new ideas or new methodology. Scientific correspondence to the Editor-in-Chief related to the published papers may also be accepted provided that they are short and scientifically relevant to the papers mentioned, in order to provide a continuing forum for discussion.